Rytus Therapeutics Limited, a under cirp public limited company, was established on 21 February 2011 in Thane, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24100MH2011PLC213828. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹6.25 Cr and a paid-up capital of ₹6.21 Cr.
It upholds a compliant status. Its leadership includes Anand Mohanty Swaroop (Whole-Time Director), Atul Laxmichand Gala (Irp/Rp/Liquidator), Abhinna Mohanty Sundar (Director). Past directors included Anand Mohanty Swaroop, Supriya Mohanty, Akhilesh Dayanand Sharma. It holds no open charges and ₹1.85 Cr settled loans. Its latest AGM occurred on 30 September 2023, with the balance sheet filed on 31 March 2023. It is based at Flat No.1601, 16Th Floor, Willowcrest Building One Hiranandani Park, Ghodbunder Road,Th, Ane West, Thane, Maharashtra, 400607.
U24100MH2011PLC213828
213828
21 February 2011
₹6.25 Cr
₹6.21 Cr
Roc Mumbai
Unlisted
Under Cirp
Explore comprehensive insights into Rytus Therapeutics Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anand Mohanty Swaroop | Whole-Time Director | 21 Feb 2011 | Current |
| Atul Laxmichand Gala | Irp/Rp/Liquidator | 24 Jun 2024 | Current |
| Abhinna Mohanty Sundar | Director | 21 Feb 2011 | Current |
| Manas Ranjan Patnaik | Additional Director | 01 Dec 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 04 Apr 2011 | Past |
| Pramod Abcsdd | Director | 01 Dec 2021 | Past |
| Pramod Abcsdd | Whole-Time Director | 11 Apr 2012 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Rytus Therapeutics Limited, for the financial year ended 2015, experienced significant growth in revenue, with a 62.76% increase. The company also saw a substantial improvement in profitability, with a 35.29% increase in profit. The company's net worth observed a substantial decline by a decrease of 251.16%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2015, Rytus Therapeutics had a promoter holding of 41.43% and a public holding of 58.57%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹18,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2013 | Axis Bank Limited | ₹1.10 Cr | Satisfied |
| 05 Oct 2011 | Tamilnad Mercantile Bank Limited | ₹7.50 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Rytus Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Rytus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rytus Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Atul Laxmichand Gala was appointed as a IRP/RP/Liquidator was appointed as a IRP/RP/Liquidator on 24 Jun 2024 & has been associated with this company since 1 year 5 months . was recorded as a recent event.
Progress on Rytus Therapeutics Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records. was documented.
The activity Rytus Therapeutics Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Mumbai. was completed.
Manas Ranjan Patnaik was appointed as a Additional Director was appointed as a Additional Director on 01 Dec 2021 & has been associated with this company since 4 years . was recorded as a recent event.
Progress on A charge registered on 26 Feb 2013 via Charge ID 10408148 with Axis Bank Limited was fully satisfied on 16 Dec 2013. was documented.
A charge with Axis Bank Limited of Rs. 1.10 Cr registered on 26 Feb 2013 with Charge ID 10408148 was modified on 09 Oct 2013. was recorded as a recent event.
The CIN of Rytus Therapeutics Limited is U24100MH2011PLC213828.
Rytus Therapeutics Limited is headquartered at Flat No.1601, 16Th Floor, Willowcrest Building One Hiranandani Park, Ghodbunder Road,Th, Ane West, Thane, Maharashtra, 400607.
Rytus Therapeutics Limited was incorporated on 21 February 2011.
The current directors of Rytus Therapeutics Limited are
The primary industry of Rytus Therapeutics Limited is Trade.
Rytus Therapeutics Limited is unlisted.
The authorized capital of Rytus Therapeutics Limited is ₹6.25 Cr, and the paid-up capital is ₹6.21 Cr.
The compliance status of Rytus Therapeutics Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX